APRETUDE

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, France, Ireland, Italy, Lithuania, Nigeria.

Active ingredients

The drug APRETUDE contains one active pharmaceutical ingredient (API):

1	Cabotegravir UNII HMH0132Z1Q - CABOTEGRAVIR
	Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.
	Read more about Cabotegravir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
APRETUDE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
APRETUDE Prolonged-release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AJ04	Cabotegravir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AJ Integrase inhibitors
Discover more medicines within J05AJ04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3045888, 3045899, 3045901
FR	Base de données publique des médicaments	62595850, 67664503
IT	Agenzia del Farmaco	050882012, 050882024, 050882036
LT	Valstybinė vaistų kontrolės tarnyba	1097789, 1097790, 1097791
NG	Registered Drug Product Database	A4-100536, A4-100537
Switch country to Nigeria in order to find specific presentations of APRETUDE
US	FDA, National Drug Code	49702-238, 49702-264